The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
On April 6, Ascendis Pharma launched YUVIWEL, the first once-weekly treatment for children with achondroplasia in the U.S. The treatment received orphan drug exclusivity until February 27, 2033. The company has already begun revenue recognition following approval and initiation of therapy for the first patients.